A new device for analyzing cancer-related exosomes in blood samples
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy
This study is testing a new device called ExoFIND that helps scientists look at tiny particles in your blood that can show signs of cancer, with the hope of making it easier to diagnose and treat the disease early on.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project ID | NIH-10627821 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nano-engineered device called ExoFIND, which aims to improve the analysis of exosomes—tiny vesicles released by cells that can carry important cancer biomarkers. By isolating and examining these exosomes from blood samples, the research seeks to identify specific proteins and RNAs that may indicate the presence and progression of cancer. This non-invasive approach could provide valuable insights for early diagnosis and targeted therapy, enhancing the precision of cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer, particularly those who may benefit from non-invasive monitoring methods.
Not a fit: Patients who do not have cancer or those whose cancer is not detectable through exosomal analysis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and earlier cancer diagnoses, as well as improved monitoring and targeted therapies for patients.
How similar studies have performed: Other research has shown promise in using exosomes for cancer diagnostics, indicating that this approach has potential based on previous findings.
Where this research is happening
Lawrence, United States
- University of Kansas Lawrence — Lawrence, United States (Active)
Researchers
- Principal investigator: Xu, Liang — University of Kansas Lawrence
- Study coordinator: Xu, Liang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.